Hematology diagnostics market seen reaching $12.86 billion by 2030

The hematology diagnostic devices and equipment market is projected to grow from $8.29 billion in 2025 to $12.86 billion by 2030, driven by blood disorder cases, chronic disease monitoring and automation. North America led the market in 2025, while AI-assisted diagnostics and point-of-care testing are emerging as key growth themes.

Why it matters: - Hematology diagnostic devices help clinicians detect and monitor blood disorders such as anemia and leukemia. - The market supports faster diagnosis and treatment decisions as blood disorder cases and chronic disease monitoring needs rise. - The category is becoming more important as labs push for greater speed, accuracy and automation.

What happened: - The Business Research Company released a 2026 report on the hematology diagnostic devices and equipment market. - The report values the market at $8.29 billion in 2025 and projects $9.13 billion in 2026. - The market is forecast to reach $12.86 billion by 2030. - The report was issued Aug. 10, 2026. - A free sample of the report is available here. - The full report is available here.

The details: - The report cites a 10.2% CAGR from 2025 to 2026 and an 8.9% CAGR through 2030. - Growth drivers include more blood disorders, more clinical diagnostic laboratories, more routine blood tests and wider use of laboratory automation. - Standardized hematology reagents are also supporting demand. - Future growth is tied to AI-assisted diagnostics, point-of-care hematology testing, personalized medicine, lab automation and early disease detection. - Key trends include automated hematology analyzers, high-throughput blood testing systems, advanced flow cytometry, integrated diagnostic platforms and faster, more accurate testing. - North America held the largest global market share in 2025. - Asia-Pacific ranked second in 2025. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company’s 2026 report updates include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, plus updated graphics and tables. - The report says hematology devices are used to analyze blood samples and detect disease. - The report says the devices improve accuracy, speed and efficiency for clinical decisions and prompt treatment.

Between the lines: - Blood disorder prevalence is a direct demand driver because hematology testing is central to detection, classification and monitoring. - Chronic disease growth widens the use case beyond specialty blood conditions and into ongoing patient management. - The regional split suggests established demand in North America and faster growth potential in Asia-Pacific and other emerging markets. - The emphasis on AI and automation points to a market shifting from basic testing toward integrated diagnostic workflows. - The Canadian Cancer Society estimates about 23,600 Canadians will be diagnosed with blood cancer in 2024. - NCBI projects the number of Americans age 50 and older living with at least one chronic illness will rise from 99.5 million to 142.66 million by 2050.

What's next: - The market is expected to keep expanding as labs adopt more automation and high-throughput testing. - Wider use of point-of-care and AI-enabled diagnostics could reshape how hematology testing is delivered. - Manufacturers will likely compete on speed, accuracy and platform integration as early disease detection becomes more central.

The bottom line: - Hematology diagnostics are moving from a steady-growth lab category to a more strategic healthcare tool as disease burden, automation and AI all increase demand.